Ticker
ABCL

Price
11.85
Stock movement up
+0.38 (3.31%)
Company name
Abcellera Biologics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
3.37B
Ent value
3.21B
Price/Sales
6.89
Price/Book
101.78
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
16.46
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-30.54%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

ABCL does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E16.46
Price to OCF14.33
Price to FCF20.32
Price to EBITDA10.99
EV to EBITDA10.47

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales6.89
Price to Book101.78
EV to Sales6.57

FINANCIALS

Per share

Loading...
Per share data
Current share count284.54M
EPS (TTM)0.73
FCF per share (TTM)0.59

Income statement

Loading...
Income statement data
Revenue (TTM)489.06M
Gross profit (TTM)463.56M
Operating income (TTM)271.37M
Net income (TTM)204.82M
EPS (TTM)0.73
EPS (1y forward)-0.48

Margins

Loading...
Margins data
Gross margin (TTM)94.79%
Operating margin (TTM)55.49%
Profit margin (TTM)41.88%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash545.72M
Net receivables334.40M
Total current assets1.17B
Goodwill47.81M
Intangible assets145.78M
Property, plant and equipment0.00
Total assets1.59B
Accounts payable10.35M
Short/Current long term debt40.28M
Total current liabilities213.42M
Total liabilities384.78M
Shareholder's equity33.13M
Net tangible assets1.01B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)235.26M
Capital expenditures (TTM)69.30M
Free cash flow (TTM)165.96M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity618.24%
Return on Assets49.01%
Return on Invested Capital618.24%
Cash Return on Invested Capital500.94%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open11.53
Daily high11.97
Daily low11.38
Daily Volume1.20M
All-time high53.20
1y analyst estimate30.00
Beta-
EPS (TTM)0.73
Dividend per share-
Ex-div date-
Next earnings date7 Nov 2022

Downside potential

Loading...
Downside potential data
ABCLS&P500
Current price drop from All-time high-77.73%-13.41%
Highest price drop-89.25%-56.47%
Date of highest drop11 May 20229 Mar 2009
Avg drop from high-62.69%-11.38%
Avg time to new high86 days12 days
Max time to new high395 days1805 days
COMPANY DETAILS
ABCL (Abcellera Biologics Inc) company logo
Marketcap
3.37B
Marketcap category
Mid-cap
Description
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Employees
400
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
VANCOUVER, British Columbia, September 21, 2022--AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic
September 21, 2022
Those following along with AbCellera Biologics Inc. ( NASDAQ:ABCL ) will no doubt be intrigued by the recent purchase...
August 24, 2022
Investors need to pay close attention to AbCellera (ABCL) stock based on the movements in the options market lately.
August 18, 2022
The contract drug developer's stock is finally shaking off the froth of its initial public offering.
August 10, 2022
Image source: The Motley Fool. AbCellera Biologics Inc. (NASDAQ: ABCL)Q2 2022 Earnings CallAug 09, 2022, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Rema...
August 10, 2022
AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -150% and 40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
August 9, 2022
VANCOUVER, British Columbia, August 09, 2022--AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial resul...
August 9, 2022
Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
August 4, 2022
VANCOUVER, British Columbia & CAMBRIDGE, Mass., August 03, 2022--AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
August 3, 2022
AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
August 2, 2022
Next page